Cardiol Therapeutics Inc - Class A
Research Cardiol Therapeutics Inc - Class A (CRDL) on Bullrun: market cap USD 142.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRDL
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 142.54M
- Financial periodQ2 2026
- RevenueCAD 0
- Net income-CAD 6.08M
- Free cash flow-CAD 4.38M
Valuation Snapshot
latest market cap is USD 142.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 33.82M | -CAD 23.88M | n/a | -0.39 | CAD 21.42M | CAD 125.52K | CAD 17.88M |
| FY2024 | CAD 0 | -CAD 36.68M | -CAD 25.08M | n/a | -0.51 | CAD 30.58M | CAD 158.53K | CAD 24.73M |
| FY2023 | CAD 0 | -CAD 28.13M | -CAD 25.24M | n/a | -0.44 | CAD 34.93M | CAD 174.34K | CAD 28.25M |
| FY2022 | CAD 0 | -CAD 30.93M | -CAD 27.30M | n/a | -0.49 | CAD 59.47M | CAD 72.87K | CAD 52.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 142.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 95.24M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 105.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 54.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 32.49M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 114.56M | n/a | n/a | n/a |
About Cardiol Therapeutics Inc - Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cardiol Therapeutics Inc - Class A's market cap?
Cardiol Therapeutics Inc - Class A's market capitalization is USD 142.54M.
What does Cardiol Therapeutics Inc - Class A do?
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure.